References
- Andersson T, Miners JO, Veronese ME, Birkett DJ. (1994). Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmac 38:131–7.
- Busby JWF, Ackermann JA, Crespi CL. (1998). Effect of methanol, ethanol, dimethyl sulpoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P450. Drug Metab Dispos 27:246–9.
- Chauret N, Gauthier A, Nicoll-Griffith DA. (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1–4.
- Easterbrook J, Lu C, Sakai Y, Li AP. (2001). Effect of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 29:141–4.
- Galetin A, Brown C, Hallifax D, Ito K, Houston JB. (2004). Utility of recombinant enzyme kinetics in prediction of human clearance: impact of valiavility, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab Dispos 32:1411–20.
- Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KHJ, Lu C, Nomeir AA, Seibert E, Skordos KW, Tonn GR, Horn RV, Wang RW, Wang YN, Yang TJ, Obach RS. (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metab Dispos 37:1355–70.
- Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM Mansuy D. (2001). Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112–22.
- Hichman D, Wang JP, Wang Y, Undakat JD. (1998). Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207–15.
- Iwase M, Kurata N, Ehana R, Nishimura Y, Masamoto T, Yasuhara H. (2006). Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug–drug interaction in vitro. Human Exp Toxicol 25:715–21.
- Kalgutkar AS, Obach RS, Maurer TS. (2007) Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interaction and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407–47.
- Kenworthy KE, Clarke SE, Andrews J, Houston JB. (2001). Multisite kinetic models for CYP3A4: Simulations activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29:1644–51.
- Li AP. (2009). Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers. Drug Metab Dispos 37:1598–603.
- Li C, Surapaneni S, Zeng QP, Marquez B, Chow D, Kumar G. (2006). Identification of a novel in vitro metabonate from liver microsomal incubations. Drug Metab Dispos 34:901–5.
- Mayhew BS, Jones DR, Hall SD. (2000). An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031–7.
- Roccatano D, Wong TS, Schwaneberg U, Zacharias M. (2005). Toward understanding the inactivation mechanism of monooxygenase P450 BM-3 by organic cosolvents: a molecular dynamics simulation study. Biopolymers 78:259–67.
- Silverman RB. (1988). The potential use of mechanism-based enzyme inactivators in medicine. J Enzyme Inhib 2:73–90.
- Wang YH, Jones DR, Hall SD. (2005). Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 33:664–71.
- Watanabe A, Nakamura K, Okudaira N, Okazaki O, Sudo K. (2007). Risk assessment for drug–drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Dispos 35:1232–8.
- Wildt SN, Kearns GL, Leeder JS, van den Anker JN. (1999). Cytochrome P450 3A: ontogeny and drug disposition. Clin Phamacokin 37:485–505.
- Yin H, Tran P, Greenberg GE, Fischer V. (2001). Methanol solvent may cause increased apparent metabolic instability in in vitro assays. Drug Metab Dispos 29:185–93.
- Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–19.